What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey among Leading International Experts

Côme Bommier; Jérôme Lambert; Grzegorz Nowakowski; Emanuele Zucca; Catherine Thieblemont

doi:10.1097/HS9.0000000000000680

What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey among Leading International Experts

Côme Bommier, Jérôme Lambert, Grzegorz Nowakowski, Emanuele Zucca, Catherine Thieblemont

Hematology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E680
Journal	HemaSphere
Volume	6
Issue number	2
DOIs	https://doi.org/10.1097/HS9.0000000000000680
State	Published - Feb 13 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.1097/HS9.0000000000000680

Cite this

@article{0aa56f7ede264deb9b1a171b309ec144,

title = "What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey among Leading International Experts",

author = "C{\^o}me Bommier and J{\'e}r{\^o}me Lambert and Grzegorz Nowakowski and Emanuele Zucca and Catherine Thieblemont",

note = "Funding Information: C.B. is funded by Assistance Publique—H{\^o}pitaux de Paris as graduate student in clinical epidemiology. No specific funding was provided to support this study.",

year = "2022",

month = feb,

day = "13",

doi = "10.1097/HS9.0000000000000680",

language = "English (US)",

volume = "6",

pages = "E680",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Wolters Kluwer Health",

number = "2",

}

TY - JOUR

T1 - What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey among Leading International Experts

AU - Bommier, Côme

AU - Lambert, Jérôme

AU - Nowakowski, Grzegorz

AU - Zucca, Emanuele

AU - Thieblemont, Catherine

N1 - Funding Information: C.B. is funded by Assistance Publique—Hôpitaux de Paris as graduate student in clinical epidemiology. No specific funding was provided to support this study.

PY - 2022/2/13

Y1 - 2022/2/13

UR - http://www.scopus.com/inward/record.url?scp=85124618514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124618514&partnerID=8YFLogxK

U2 - 10.1097/HS9.0000000000000680

DO - 10.1097/HS9.0000000000000680

M3 - Letter

AN - SCOPUS:85124618514

SN - 2572-9241

VL - 6

SP - E680

JO - HemaSphere

JF - HemaSphere

IS - 2

ER -

What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey among Leading International Experts

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this